share_log

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target

Benzinga ·  Aug 16 00:48  · Ratings

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $60 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment